Obermatt
See Similar Stocks →

Rapport Therapeutics

NMQ:RAPP · US75383L1026
PharmaceuticalsSmall

360

13
Medium confidence — indicative
Profit price83
Owner Earnings Yield1
Dividend Yield1
Price/Sales4
EV / Gross Profit3
Price/Book17
Return on Capital19
Cash Return on Capital20
Return on Equity27
Profit margins13
Accruals5
Owner Earnings Margin9
Sales growth—
Profit growth16
Reinvestment10
Price momentum92
Debt load70
Refinancing54
Debt Payback1
Liquidity25
Analyst ratings82
Opinion Changes50
Price Target Upside60
Market mood27
Value Creation5/20not creating value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Rapport Therapeutics doesn't consistently earn more than its cost of capital, so it isn't yet creating shareholder value.

Based on 4/5 components.

Profile

CountryUSA
IndustryPharmaceuticals
SizeSmall
TypePublic Company
ExchangeNASDAQGM
Founded2022
Websiterapportrx.com
ISINUS75383L1026
Last UpdateApr 2, 2026
Indices
NASDAQ (USA)
Themes
NeurologyChronic DiseasesPain ManagementCentral Nervous SystemNeuroscienceGeneticsPsychiatryBiotechnologyHealth CareLife ScienceMedical

Description

Rapport Therapeutics, Inc. is a clinical-stage biotechnology company. The company is dedicated to the discovery and development of small molecule precision medicines for patients with neurological or psychiatric disorders. The company’s deep experti…

Analysis

Weak and unloved

Rapport Therapeutics, Inc. is weak and unloved: below-average business metrics and a price that reflects that disappointment.

Valuation data is not available for this company.

The trajectory is mixed and the balance sheet is stretched. The company scores 5/20 on our value-creation score: not creating value.

Nothing is flagged here: no red or amber gates, no divergence between profits and cash. That is itself information: the numbers are straightforward. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250
30
2026

All-time high

30

Jun 2026

All-time low

23

Mar 2026

Average rank

27

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
4
—
—
—
Price/Earnings
83
—
—
—
Price/Book
17
—
—
—
Dividend Yield
1
—
—
—
Value (overall)
21
—
—
—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Rapport Therapeutics with its peers
Pliant Therapeutics
NSQ:PLRX
41
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Terns Pharmaceuticals
NSQ:TERN
96
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Insmed
NSQ:INSM
51
CountryUSA
IndustryBiotechnology
SizeMedium
Full Stock Analysis →
Nektar
NAQ:NKTR
4
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
NRX Pharmaceuticals
NAQ:NRXP
49
CountryUSA
IndustryPharmaceuticals
SizeX-Small
Full Stock Analysis →
Adicet Bio
NAQ:ACET
26
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →